Clinical trials
Antibody clinical trials
Below are recruiting antibody clinical trials, each written for real people, not researchers. We’re tracking 519 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05384509Recruiting
Tracking antibody levels in cancer patients during COVID vaccines
This study measures COVID “neutralizing” antibodies over time in people with cancer who are on different kinds of cancer treatments. It aims to understand how vaccination and treatment type affect immune protection in cancer patients.
New Taipei CityAges 20 years+ - NCT07355699RecruitingPhase 4
Orelabrutinib for untreated marginal zone lymphoma
This trial tests a new targeted drug (orelabrutinib) with or without another drug that targets CD20 (a protein on some immune cells) for people with untreated marginal zone lymphoma. It aims to see if this combination works better than other treatments and may be an option for those who cannot have radiation.
BeijingAges 18 years+ - NCT07356050Recruiting
Measles vaccine study for children with sickle cell disease
This study checks if the measles vaccine works well in children with sickle cell disease. It aims to help protect children with this condition from measles.
Cincinnati, OhioAges 6 months–6 years - NCT06849622Recruiting
Blood spot test for type 1 diabetes and celiac disease
This study tests a new way to check for type 1 diabetes and celiac disease using a tiny drop of blood from a finger prick, instead of a regular blood draw. The goal is to make diagnosis easier and less scary for children.
Florence, ItalyAges 2–13 - NCT06170489RecruitingPhase 3
Study of JS004 plus toripalimab for Hodgkin lymphoma
This study tests a new combination of two drugs (JS004 plus toripalimab) versus standard chemotherapy for people with Hodgkin lymphoma that no longer responds to PD-1/PD-L1 immunotherapy. The goal is to see if the new combination works better.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06851299RecruitingPhase 2
Trop2-ADC alone or with immunotherapy for advanced triple-negative breast cancer
This study tests a new drug called Trop2-ADC, either alone or combined with immunotherapy, for people with advanced triple-negative breast cancer. The goal is to see if it can shrink tumors and improve outcomes.
Guangzhou, GuangdongAges 18–70 - NCT07347769Recruiting
BK virus risk study in kidney transplant patients
This study looks at the type and genetic makeup of BK virus in kidney transplant patients and their donors. It aims to find patients at higher risk for a kidney infection caused by the virus, which could help improve monitoring and treatment.
GrenobleAges 18 years+ - NCT04777084RecruitingPhase 2
Lenvatinib plus PD-1 antibody for advanced lung cancer
This Phase 2 study tests whether a combination of lenvatinib and a PD-1/PD-L1–blocking antibody (IBI318) can shrink advanced non-small cell lung cancer and is safe to use. It targets people whose cancer has specific genetic changes or specific prior treatment history, based on three different study groups.
Changsha, HunanAges 18–75 - NCT06865274Recruiting
A look at gene changes in MS, NMOSD, and MOGAD
This study looks at a specific gene change in people with MS, NMOSD, or MOGAD to see how common it is. By joining, you help researchers learn more about these conditions and possible future treatments.
Roma, RomaAges 18 years+ - NCT07328854RecruitingPhase 3
Lower versus standard radiation in stage II nasopharyngeal cancer
This trial compares a lower dose of radiation (40.2 Gy) to the standard dose (49.2 Gy) for patients with stage II nasopharyngeal carcinoma that has shrunk after initial chemoimmunotherapy. The goal is to see if the lower dose works just as well while potentially causing fewer side effects.
Hefei, AnhuiAges 18–75 - NCT07319429RecruitingPhase 2/Phase 3
Fertility-sparing treatment for endometrial cancer based on molecular type
This trial tests a tailored approach to preserve fertility in women with early-stage endometrial cancer, using medications like hormones and immunotherapy based on the tumor's molecular subtype. It aims to avoid hysterectomy and keep the uterus intact.
Shanghai, Shanghai MunicipalityAges 18–45 - NCT04365036RecruitingPhase 3
Check if PD-1 plus chemo-radiation helps early nasal lymphoma
This trial studies whether adding toripalimab (an immune therapy that targets PD-1) to standard chemo-radiation works better for newly diagnosed early-stage nasal natural killer/T-cell lymphoma. It’s designed to see if the combined treatment can improve outcomes while staying safe.
Guangzhou, GuangdongAges 18–75 - NCT07309770RecruitingPhase 2
Trastuzumab Rezetecan for advanced solid tumors that have stopped responding to standard treatments
This trial tests a new drug called Trastuzumab Rezetecan in people with advanced solid tumors that are HER2-positive and have not responded to standard therapies. It includes three specific groups: people with extramammary Paget's disease, rare solid tumors, or urothelial carcinoma. The goal is to see if this drug can shrink tumors or slow their growth.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07297563RecruitingPhase 2
Anti-CD38 antibody vs rituximab for hard-to-treat ITP
This trial tests a new antibody drug (anti-CD38) compared to a standard drug (rituximab) for adults with ITP that hasn't responded well to steroids. The goal is to see if the new drug works better at raising platelet counts and reducing bleeding risk.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07301827Recruiting
New PET imaging for kidney cancer diagnosis
This study tests a new kind of PET scan that might better detect kidney cancer. It involves an injection of a special imaging agent and a scan to see if the cancer shows up clearly.
Wuhan, HubeiAges 18 years+ - NCT07293754RecruitingPhase 1/Phase 2
Study of RPTR-1-201 for advanced solid tumors
This trial tests a new drug called RPTR-1-201 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
Grand Rapids, MichiganAges 18 years+ - NCT06881537RecruitingPhase 2
Chemo and targeted therapy before surgery for recurrent colorectal cancer
This trial tests a combination of chemotherapy (CapeOX), a targeted drug (bevacizumab), and an immunotherapy (anti-PD1) given before surgery for colorectal cancer that has come back locally (in the same area). The goal is to shrink the tumor and improve surgical outcomes.
ShanghaiAges 18–75 - NCT07285213RecruitingPhase 2
Preventing C. diff return with an antibody
This study tests a new antibody (AZD5148) to prevent C. diff infection from coming back. If you have a current C. diff infection and are being treated with antibiotics, you may be able to join.
Phoenix, ArizonaAges 18 years+ - NCT03956446Recruiting
Testing blood antibody patterns in tick-borne brain and Lyme illness
This study looks at blood antibody test results in adults who may have tick-borne encephalitis and also signs of Lyme disease. It may help researchers understand how these infections relate and which lab patterns fit different illnesses.
LjubljanaAges 18 years+ - NCT05713994Recruiting
Liver cancer treatments together for unresectable liver tumors
This trial tests a combined treatment plan—chemo delivered to the liver, targeted therapy, anti-VEGF therapy, and immunotherapy—to control unresectable hepatocellular carcinoma (HCC). It may help shrink tumors or slow progression when surgery isn’t possible.
Quanzhou, FujianAges 18 years+ - NCT07266428RecruitingPhase 1/Phase 2
Study of a new drug (OTP-01) for advanced solid tumors
This trial is testing a new drug called OTP-01 that targets two proteins (PD-1 and VEGFR2) to help your immune system fight cancer and stop tumors from growing. It is for people with advanced solid tumors that have not responded to or cannot have standard treatments.
New Haven, ConnecticutAges 18 years+ - NCT07268053RecruitingEarly Phase 1
B7-H3 drug for recurrent brain tumor or brain metastases
This trial tests a drug called GSK5764227 (a B7-H3 targeted antibody-drug conjugate) in people whose glioblastoma has come back after standard treatment, or who have brain metastases that need surgery. The goal is to see if the drug can help shrink or control the tumor.
Phoenix, ArizonaAges 18 years+ - NCT07258511RecruitingPhase 3
Comparing a new drug to Teclistamab for advanced multiple myeloma
This study tests a new experimental drug (JNJ-79635322) compared to another targeted immunotherapy (Teclistamab) for people with multiple myeloma that has returned or not responded after several prior treatments.
Phoenix, ArizonaAges 18 years+ - NCT07247279Recruiting
Study of myasthenia gravis treatments in Russia
This study tracks how generalized myasthenia gravis (a condition that causes muscle weakness) is treated in Russia. By looking at real-world data, researchers hope to learn more about which treatments work best for people like you.
Kazan'Ages 18 years+
Hear when a new Antibody trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for antibody?
- Yes. Clin2 currently lists 519 recruiting antibody studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a antibody trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a antibody trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.